Prostatype Genomics AB
Research Prostatype Genomics AB (PROGEN) on Bullrun: market cap SEK 24.27M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPROGEN
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencySEK
- Market capSEK 24.27M
- Financial periodFY2025
- RevenueSEK 594.00K
- Revenue growth198.5%
- Net income-SEK 44.50M
- Free cash flow-SEK 37.24M
- Gross margin100.0%
Valuation Snapshot
latest market cap is SEK 24.27M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 594.00K | -SEK 44.50M | -SEK 37.24M | 100.0% | -1.32 | SEK 9.07M | n/a | SEK 26.53M |
| FY2024 | SEK 199.00K | -SEK 41.05M | -SEK 52.57M | 963.8% | -14.93 | SEK 9.42M | SEK 67.00K | SEK 33.47M |
| FY2023 | SEK 1.36M | -SEK 41.44M | -SEK 37.70M | 274.9% | -187.95 | SEK 2.68M | SEK 11.67M | SEK 24.67M |
| FY2022 | SEK 683.00K | -SEK 29.09M | -SEK 27.69M | 100.0% | -323.24 | SEK 4.81M | SEK 867.00K | SEK 26.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 24.27M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Prostatype Genomics AB
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Prostatype Genomics AB's market cap?
Prostatype Genomics AB's market capitalization is SEK 24.27M.
What does Prostatype Genomics AB do?
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Nacka, Sweden.